Predictive Value of Maternal Serum Markers for Preeclampsia

Article information

Kosin Med J. 2012;27(2):91-97

Publication date (electronic) : 2012 January 19

doi : https://doi.org/10.7180/kmj.2012.27.2.91

¹Department of Laboratory Medicine, Wonjin Green Hospital, Seoul, Korea

²Department of Obsterics and Gynecology, College of Medicine, Kosin University, Busan, Korea

Corresponding author: Heung Yeol Kim, Department of Obstetrics and Gynecology, College of Medicine, Kosin University, 34, Amnamdong, Seo-gu, Busan, 602-702, Korea TEL: +82-51-990-6226 FAX: +82-51-990-3300 E-mail: hykyale@yahoo.com

Received 2012 October 08; 2012 October 09; Accepted 2012 October 17.

Abstract

The study performed a systematic review of screening for preeclampsia with the combination of vascular parameters and maternal serum markers in the first and early second trimester. We identified eligible studies through a search of Medline, and, for each included study, we focused on the relationship between the maternal serum markers and preeclampsia. In the selected literature, a combination of maternal serum markers was analyzed, also. Several tests suggested moderate or convincing prediction of early preeclampsia, but screening for late preeclampsia was poor. Literatures for serum markers were selected. Each serum marker was identified independently, and where relevant, a combination of these markers was analyzed. Encouraging results for the first trimester screening were observed when it was combined with other markers. Even in the first trimester of pregnancy, we can present the reliable results for the prediction of early preeclampsia. Detection rate for combination markers may yield higher detection rate and be promising to identify patients at high risk of developing preeclampsia.

Keywords: Blood Pressure; Biological Markers; Pre-Eclampsia; Screening

References

1. Saftlas AF, Olson DR, Franks AL, Atrash HK, Pokras R. Epidemiology ofpreeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990;163:460–5.

2. Borzychowski AM, Sargent IL, Redman CW. Inflammationand pre-eclampsia. Semin Fetal Neonatal Med 2006;11:309–16.

3. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631–44.

4. Huppertz B. Placental origins of preeclampsia: challengingthe current hypothesis. Hypertension 2008;51:970–5.

5. Leslie K, Thilaganathan B, Papageorghiou A. Early prediction andprevention of pre-eclampsia. Best Pract Res Clin Obstet Gynaecol 2011;25:343–54.

6. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. Fetal Medicine Foundation Second Trimester Screening Group. An integrated model for the prediction ofpreeclampsia using maternal factors and uterine artery Doppler velocimetry inunselected low-risk women. Am J Obstet Gynecol 2005;193:429–36.

7. Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K. First-trimester markers for the prediction ofpreeclampsia in women with a-priori high risk. Ultrasound Obstet Gynecol 2010;35:671–9.

8. Giguère Y, Charland M, Bujold E, Bernard N, Grenier S, Rousseau F, et al. Combining biochemical and ultrasonographic markers in predicting preeclampsia: a systematic review. Ann BiolClin 2011;69:257–1.

9. Farina A, Zucchini C, Sekizawa A, Purwosunu Y, de Sanctis P, Santarsiero G, et al. Performance of messenger RNA scirculating in maternal blood in the prediction of preeclampsia at 10-14 weeks. Am J Obstet Gynecol 2010;203:e1–7.

10. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 2004;104:1367–91.

11. Redman CW. Current topic: pre-eclampsia and the placenta. Placenta 1991;12:301–8.

12. Costa SL, Proctor L, Dodd JM, Toal M, Okun N, Johnson JA, et al. Screening for placental insufficiency in high-risk pregnancies: is earlier better? Placenta 2008;29:1034–40.

13. Cindrova-Davies T, Spasic-Boskovic O, Jauniaux E, Charnock-Jones DS, Burton GJ. Nuclear factor-kappa B, p38, and stress-activated protein kinase mitogen-activated protein kinase signaling pathways regulate proinflammatory cytokines and apoptosis in human placental explants in response to oxidative stress: effects of antioxidant vitamins. Am J Pathol 2007;170:1511–20.

14. Bosio PM, Cannon S, McKenna PJ, O'Herlihy C, Conroy R, Brady H. Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG 2001;108:709–15.

15. Bersinger NA, Smárason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels ofpregnancy-associated plasma protein A (PAPP-A), inhibinA, activin A and soluble E-selectin. Hypertens Pregnancy 2003;22:45–55.

16. Giudice LC, Conover CA, Bale L, Faessen GH, Ilg K, Sun I, et al. Identification andregulation of the IGFBP-4 protease and its physiologicalinhibitor in human trophoblasts and endometrial stroma: evidencefor paracrine regulation of IGF-II bioavailability in theplacental bed during human implantation. J Clin Endocrinol Metab 2002;87:2359–66.

17. Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol 2010;8:102.

18. Lee LC, Sheu BC, Shau WY, Liu DM, Lai TJ, Lee YH, et al. Mid-trimester beta-hCG levels incorporated in a multifactorial model for the prediction of severe pre-eclampsia. Prenat Diagn 2000;20:738–43.

19. Birdsall M, Ledger W, Groome N, Abdalla H, Muttukrishna S. Inhibin A and activin A in the first trimester of human pregnancy. J Clin Endocrinol Metab 1997;82:1557–60.

20. Muttukrishna S, Knight PG, Groome NP, Redman CW, Ledger WL. Activin A and inhibin A as possible endocrine markers for pre-eclampsia. Lancet 1997;349:1285–8.

21. Sekizawa A, Purwosunu Y, Yoshimura S, Nakamura M, Shimizu H, Okai T, et al. PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci 2009;16:408–13.

22. Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, et al. Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004;25:608–22.

23. Lockwood CJ, Krikun G, Caze R, Rahman M, Buchwalder LF, Schatz F. Decidual cell expressed tissue factor in human pregnancy and its involvement in hemostasis and preeclampsia-related angiogenesis. Ann N Y AcadSci 2008;1127:67–72.

24. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83.

25. Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, et al. The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med 2008;21:279–87.

26. Gack S, Marmé A, Marmé F, Wrobel G, Vonderstrass B, Bastert G, et al. Preeclampsia: increased expression of soluble ADAM 12. J Mol Med 2005;83:887–96.

27. Spencer K, Cowans NJ, Stamatopoulou A. ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn 2008;28:212–6.

28. Wortelboer EJ, Koster MP, Cuckle HS, Stoutenbeek PH, Schielen PC, Visser GH. First-trimester placental protein 13 and placental growth factor: markers for identification of women destined to develop early-onset preeclampsia. BJOG 2010;117:1384–9.

Article information Continued

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.